Simcere Pharmaceutical Group Limited (HKG:2096)

Market Cap	35.18B +79.5%
Revenue (ttm)	8.60B +16.5%
Net Income	1.50B +83.3%
EPS	0.60 +86.2%
Shares Out	2.58B
PE Ratio	22.67
Forward PE	19.03
Dividend	0.20 (1.50%)
Ex-Dividend Date	Jun 17, 2026

Volume	11,252,745
Average Volume	5,668,078
Open	13.53
Previous Close	13.52
Day's Range	13.03 - 13.73
52-Week Range	7.07 - 15.08
Beta	0.79
RSI	68.09
Earnings Date	Mar 25, 2026

About HKG:2096

Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENW...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1995
• Employees: 6,815
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2096

Financial Performance

In 2025, HKG:2096's revenue was 7.73 billion, an increase of 16.52% compared to the previous year's 6.64 billion. Earnings were 1.34 billion, an increase of 83.32%.

Financial numbers in CNY